nach oben

Current Atherosclerosis Reports

Erschienen in:

01.02.2018 | Evidence-Based Medicine (L. Roever, Section Editor)

Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update

verfasst von: Hugo Ribeiro Zanetti, Leonardo Roever, Alexandre Gonçalves, Elmiro Santos Resende

Erschienen in: Current Atherosclerosis Reports | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This clinical update is intended to focus in relationship between HIV infection and use of antiretroviral therapy (ART) and statin.

Recent Findings

Though ART significantly changed the course of HIV infection, it is related to numerous side effects principally to the lipid profile. In this way, statins became one of the most used lipid-lowering therapies in this population. In our clinical update, we evaluated studies that demonstrate the relationship and molecular mechanisms that HIV infection and ART use trigger dyslipidemia and also the use of statin to reduce this condition.

Summary

We have demonstrated that use of statin can be used in dyslipidemic HIV-infected people as long as there is no drug interaction with ART. Recently, studies using rosuvastatin have shown greater effects when compared to the other statins.

• Malta M, da Silva CM, Magnanini MM, et al. Improvement of HAART in Brazil, 1998–2008: a nationwide assessment of survival times after AIDS diagnosis among men who have sex with men. BMC Public Health. 2015;15:1530. This study shows the improvement of ART in HIV infection.CrossRef

Venturini A, Giannini B, Montefiori M, di Biagio A, Mazzarello G, Cenderello G, et al. Quality of life of people living with HIV, preliminary results from IANUA (Investigation on Antiretroviral Therapy) study. J Int AIDS Soc. 2014;17(4 Suppl 3):19581. https://doi.org/10.7448/IAS.17.4.19581.CrossRefPubMedPubMedCentral

Chanu B, Valensi P. Lipid disorders in patients with HIV-induced diseases. Presse Med. 2005;34(15):1087–94. https://doi.org/10.1016/S0755-4982(05)84124-7.CrossRefPubMed

• Munger AM, Chow DC, Playford MP, Parikh NI, Gangcuangco LMA, Nakamoto BK, et al. Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens. AIDS Res Hum Retrovir. 2015;31(2):221–8. The study characterizes the lipid profile among HIV-infected people. https://doi.org/10.1089/aid.2014.0239.CrossRefPubMedPubMedCentral

Parakh A, Dubey AP, Kumar A, Maheshwari A. Lipodystrophy and metabolic complications of highly active antiretroviral therapy. Indian J Pediatr. 2009;76(10):1017–21. https://doi.org/10.1007/s12098-009-0216-9.CrossRefPubMed

Group DADS, Friis-Moller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–35.CrossRef

Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993–2003. https://doi.org/10.1056/NEJMoa030218.CrossRefPubMed

•• Esser S, Eisele L, Schwarz B, Schulze C, Holzendorf V, Brockmeyer NH, et al. Rates of cardiovascular events and deaths are associated with advanced stages of HIV-infection: results of the HIV HEART study 7, 5 year follow-up. J Int AIDS Soc. 2014;17(4 Suppl 3):19542. The article demonstrated the development of cardiovascular disease in HIV-infected people. https://doi.org/10.7448/IAS.17.4.19542.CrossRefPubMedPubMedCentral

Kuller LH, Tracy R, Belloso W, Wit SD, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203. https://doi.org/10.1371/journal.pmed.0050203.CrossRefPubMedPubMedCentral

10.

Rajasuriar R, Khoury G, Kamarulzaman A, French MA, Cameron PU, Lewin SR. Persistent immune activation in chronic HIV infection: do any interventions work? AIDS. 2013;27(8):1199–208. https://doi.org/10.1097/QAD.0b013e32835ecb8b.CrossRefPubMedPubMedCentral

11.

Falcao MC, Zirpoli JC, Albuquerque VM, et al. Association of biomarkers with atherosclerosis and risk for coronary artery disease in patients with HIV. Arq Bras Cardiol. 2012;99:971–8.CrossRefPubMed

12.

Gleeson M. Immune function in sport and exercise. J Appl Physiol. 2007;103(2):693–9. https://doi.org/10.1152/japplphysiol.00008.2007.CrossRefPubMed

13.

Shikuma CM, Gangcuangco LM, Killebrew DA, et al. The role of HIV and monocytes/macrophages in adipose tissue biology. J Acquir Immune Defic Syndr. 2014;65(2):151–9. https://doi.org/10.1097/01.qai.0000435599.27727.6c.CrossRefPubMedPubMedCentral

14.

Esser S, Gelbrich G, Brockmeyer N, Goehler A, Schadendorf D, Erbel R, et al. Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study. Clin Res Cardiol. 2013;102(3):203–13. https://doi.org/10.1007/s00392-012-0519-0.CrossRefPubMed

15.

Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13(8):453–68. https://doi.org/10.1111/j.1468-1293.2012.00996.x.PubMed

16.

Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J. 2014;35(21):1373–81. https://doi.org/10.1093/eurheartj/eht528.CrossRefPubMed

17.

Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34. https://doi.org/10.1097/01.qai.0000233310.90484.16.CrossRefPubMed

18.

Tiwari A, Bansal V, Chugh A, Mookhtiar K. Statins and myotoxicity: a therapeutic limitation. Expert Opin Drug Saf. 2006;5(5):651–66. https://doi.org/10.1517/14740338.5.5.651.CrossRefPubMed

19.

Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58(23):2432–46. https://doi.org/10.1016/j.jacc.2011.10.824.CrossRefPubMed

20.

Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78. https://doi.org/10.1016/S0140-6736(05)67394-1.CrossRefPubMed

21.

Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.CrossRef

22.

Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–8. https://doi.org/10.1001/jama.285.13.1711.CrossRefPubMed

23.

Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152–60. https://doi.org/10.1016/S0002-9149(03)00530-7.CrossRefPubMed

24.

Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58. https://doi.org/10.1016/S0140-6736(03)12948-0.CrossRefPubMed

25.

Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–504. https://doi.org/10.1056/NEJMoa040583.CrossRefPubMed

26.

Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson Å, McMurray JV, et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail. 2005;7(6):1059–69. https://doi.org/10.1016/j.ejheart.2005.09.005.CrossRefPubMed

27.

Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004;6(5):635–41. https://doi.org/10.1016/j.ejheart.2004.03.001.CrossRefPubMed

28.

The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365–74.CrossRef

29.

Ito MK, Talbert RL, Tsimikas S. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction. Pharmacotherapy. 2006;26(7part2):85S–97S; discussion 8S–101S; quiz 6S–8S. https://doi.org/10.1592/phco.26.7part2.85S.CrossRefPubMed

30.

Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14(1):37–44. https://doi.org/10.1016/j.molmed.2007.11.004.CrossRefPubMedPubMedCentral

31.

Zeiser R, Maas K, Youssef S, Durr C, Steinman L, Negrin RS. Regulation of different inflammatory diseases by impacting the mevalonate pathway. Immunology. 2009;127(1):18–25. https://doi.org/10.1111/j.1365-2567.2008.03011.x.CrossRefPubMedPubMedCentral

32.

Laufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep. 2003;5(5):372–8. https://doi.org/10.1007/s11883-003-0008-z.CrossRefPubMedPubMedCentral

33.

Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45(1):89–118. https://doi.org/10.1146/annurev.pharmtox.45.120403.095748.CrossRefPubMedPubMedCentral

34.

Zhou Q, Liao JK. Pleiotropic effects of statins—basic research and clinical perspectives. Circ J. 2010;74(5):818–26. https://doi.org/10.1253/circj.CJ-10-0110.CrossRefPubMedPubMedCentral

35.

Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150(12):858–68. https://doi.org/10.7326/0003-4819-150-12-200906160-00009.CrossRefPubMed

36.

Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc DrugsTher. 2005;19(6):403–14. https://doi.org/10.1007/s10557-005-5686-z.

37.

Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15. https://doi.org/10.1016/j.jacl.2012.03.003.CrossRefPubMed

38.

Echaniz-Laguna A, Mohr M, Tranchant C. Neuromuscular symptoms and elevated creatine kinase after statin withdrawal. N Engl J Med. 2010;362(6):564–5. https://doi.org/10.1056/NEJMc0908215.CrossRefPubMed

39.

Cohen DE, Anania FA, Chalasani N, National Lipid Association Statin Safety Task Force Liver Expert P. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97(8A):77C–81C. https://doi.org/10.1016/j.amjcard.2005.12.014.CrossRefPubMed

40.

Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32(10):1924–9. https://doi.org/10.2337/dc09-0738.CrossRefPubMedPubMedCentral

41.

•• Thakker D, Nair S, Pagada A, Jamdade V, Malik A. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf. 2016;25(10):1131–49. This meta analysis shows an important data of side effects of statin use. https://doi.org/10.1002/pds.4020.CrossRefPubMed

42.

Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289(22):2978–82. https://doi.org/10.1001/jama.289.22.2978.CrossRefPubMed

43.

Samaras K. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother. 2008;61(2):238–45. https://doi.org/10.1093/jac/dkm475.CrossRefPubMed

44.

Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53(1):10–4. https://doi.org/10.1093/jac/dkh013.CrossRefPubMed

45.

Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351(9119):1881–3. https://doi.org/10.1016/S0140-6736(98)03391-1.CrossRefPubMed

46.

D'Ascenzo F, Agostoni P, Abbate A, Castagno D, Lipinski MJ, Vetrovec GW, et al. Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials. Atherosclerosis. 2013;226(1):178–85. https://doi.org/10.1016/j.atherosclerosis.2012.10.065.CrossRefPubMed

47.

Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy. 2000;20(9):1066–71. https://doi.org/10.1592/phco.20.13.1066.35033.CrossRefPubMed

48.

Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One. 2011;6(7):e21843. https://doi.org/10.1371/journal.pone.0021843.CrossRefPubMedPubMedCentral

49.

Causevic-Ramosevac A, Semiz S. Drug interactions with statins. Acta Pharma. 2013;63(3):277–93. https://doi.org/10.2478/acph-2013-0022.CrossRef

50.

Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52(10):815–31. https://doi.org/10.1007/s40262-013-0075-4.CrossRefPubMed

51.

Stein JH, Merwood MA, Bellehumeur JL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J. 2004;147:E18.PubMed

52.

Hurlimann D, Chenevard R, Ruschitzka F, et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial. Heart. 2006;92(1):110–2. https://doi.org/10.1136/hrt.2004.056523.CrossRefPubMedPubMedCentral

53.

Mallon PW, Miller J, Kovacic JC, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men—a randomized, placebo-controlled study. AIDS. 2006;20(7):1003–10. https://doi.org/10.1097/01.aids.0000222072.37749.5a.CrossRefPubMed

54.

Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res. 2008;6(6):572–8. https://doi.org/10.2174/157016208786501481.CrossRefPubMed

55.

Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS. 2010;24(1):77–83. https://doi.org/10.1097/QAD.0b013e328331d2ab.CrossRefPubMed

56.

Calza L, Trapani F, Bartoletti M, Manfredi R, Colangeli V, Borderi M, et al. Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-alpha in HIV-infected patients treated with ritonavir-boosted protease inhibitors. HIV Clin Trials. 2012;13(3):153–61. https://doi.org/10.1310/hct1303-153.CrossRefPubMed

57.

• Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209(8):1156–64. The article demonstrates the pleiotropic effects of statin in HIV people. https://doi.org/10.1093/infdis/jiu012.CrossRefPubMedPubMedCentral

58.

Longenecker CT, Hileman CO, Funderburg NT, McComsey GA. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial. Clin Infect Dis. 2014;59(8):1148–56. https://doi.org/10.1093/cid/ciu523.CrossRefPubMedPubMedCentral

59.

•• Gili S, Grosso Marra W, D'Ascenzo F, Lonni E, Calcagno A, Cannillo M, et al. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. Eur Heart J. 2016. A very good review on effects of statin in HIV patients.;37(48):3600–9. https://doi.org/10.1093/eurheartj/ehv734.CrossRefPubMed

60.

•• Lichtenstein KA, Hart RL, Wood KC, Bozzette S, Buchacz K, Brooks JT, et al. Statin use is associated with incident diabetes mellitus among patients in the HIV outpatient study. J Acquir Immune Defic Syndr. 2015;69(3):306–11. The article demonstrates the association between the use of statin and incidence of diabetes. https://doi.org/10.1097/QAI.0000000000000581.CrossRefPubMedPubMedCentral

Titel: Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update
verfasst von: Hugo Ribeiro Zanetti
Leonardo Roever
Alexandre Gonçalves
Elmiro Santos Resende
Publikationsdatum: 01.02.2018
Verlag: Springer US
Erschienen in: Current Atherosclerosis Reports / Ausgabe 2/2018
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-018-0708-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Microvascular Coronary Dysfunction—an Overview

Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis

Nutrition and Cardiovascular Disease—an Update